News
-
-
-
COMMUNIQUÉ DE PRESSE
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
APONTIS PHARMA AG waives minimum acceptance condition in Zentiva's public purchase offer. Around 60% shares tendered. Management recommends acceptance. Cash consideration offers premium -
COMMUNIQUÉ DE PRESSE
Original-Research: APONTIS PHARMA AG (von Montega AG): Verkaufen (zuvor: Halten)
Montega AG stuft APONTIS PHARMA AG von Verkaufen auf Halten herab und senkt das Kursziel auf 10,00 EUR. Umsatzprognose gesenkt auf 48,7 Mio. EUR aufgrund verzögerter Wirkung der neuen Vertriebsstrategie -
-
-
COMMUNIQUÉ DE PRESSE
EV Nickel Reports Precious Metals Assays Associated with Elevated Nickel Mineralization in Hole Ev24-Car08 on the CarLang C Zone
EV Nickel Inc. announces significant nickel mineralization with high PGM values in CarLang C area, indicating potential for magmatic sulphide source. Exploration and testing programs ongoing -
-
-
COMMUNIQUÉ DE PRESSE
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024, with revenue guidance adjusted. Novartis collaboration boosts revenues. Full-year forecast slightly lowered
